| Acquired by | Oxigene |
| Price | $34.2M |
| Date | 7/09 |
| Website | symphonyvida.com |
| Category | BioTech |
| Employees | |
| Founded | 2008 |
| Description | oncology products |
Symphony ViDA, Inc. operates as a biopharmaceutical company. It offers services for the development of OXi4503, which is used for the treatment of various forms of cancer; and ZYBRESTAT that is used for the treatment of neovascular diseases of the eye. The company was incorporated in 2008 and is based in Rockville, Maryland. As of July 20, 2009, Symphony ViDA, Inc. operates as a subsidiary of Oxigene Inc.
